JP7053037B2 - 治療薬 - Google Patents

治療薬 Download PDF

Info

Publication number
JP7053037B2
JP7053037B2 JP2018503642A JP2018503642A JP7053037B2 JP 7053037 B2 JP7053037 B2 JP 7053037B2 JP 2018503642 A JP2018503642 A JP 2018503642A JP 2018503642 A JP2018503642 A JP 2018503642A JP 7053037 B2 JP7053037 B2 JP 7053037B2
Authority
JP
Japan
Prior art keywords
immune response
cells
cell
cell according
receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018503642A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018521663A (ja
JP2018521663A5 (enExample
Inventor
マーハー，ジョン
ヨルダノヴァ アチコヴァ，ダニエラ
メイ ワイルディング，リンジー
オーウェン ドレイパー，ベンジャミン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kings College London
Original Assignee
Kings College London
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kings College London filed Critical Kings College London
Publication of JP2018521663A publication Critical patent/JP2018521663A/ja
Publication of JP2018521663A5 publication Critical patent/JP2018521663A5/ja
Priority to JP2021114022A priority Critical patent/JP2021168675A/ja
Application granted granted Critical
Publication of JP7053037B2 publication Critical patent/JP7053037B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4203—Receptors for growth factors
    • A61K40/4205—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4214—Receptors for cytokines
    • A61K40/4215—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR], CD30
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4214—Receptors for cytokines
    • A61K40/4216—Receptors for colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4231—Cytokines
    • A61K40/4234—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/27—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by targeting or presenting multiple antigens
    • A61K2239/29—Multispecific CARs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2018503642A 2015-07-31 2016-07-28 治療薬 Active JP7053037B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021114022A JP2021168675A (ja) 2015-07-31 2021-07-09 治療薬

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1513540.3A GB201513540D0 (en) 2015-07-31 2015-07-31 Therapeutic agents
GB1513540.3 2015-07-31
PCT/GB2016/052324 WO2017021701A1 (en) 2015-07-31 2016-07-28 Therapeutic agents

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021114022A Division JP2021168675A (ja) 2015-07-31 2021-07-09 治療薬

Publications (3)

Publication Number Publication Date
JP2018521663A JP2018521663A (ja) 2018-08-09
JP2018521663A5 JP2018521663A5 (enExample) 2019-08-29
JP7053037B2 true JP7053037B2 (ja) 2022-04-12

Family

ID=54062973

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018503642A Active JP7053037B2 (ja) 2015-07-31 2016-07-28 治療薬
JP2021114022A Pending JP2021168675A (ja) 2015-07-31 2021-07-09 治療薬

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021114022A Pending JP2021168675A (ja) 2015-07-31 2021-07-09 治療薬

Country Status (15)

Country Link
US (6) US10703794B2 (enExample)
EP (2) EP3939992A1 (enExample)
JP (2) JP7053037B2 (enExample)
KR (1) KR102411571B1 (enExample)
CN (1) CN107735407B (enExample)
AU (1) AU2016303355B2 (enExample)
CA (1) CA2993746A1 (enExample)
DK (1) DK3328880T3 (enExample)
ES (1) ES2883633T3 (enExample)
GB (1) GB201513540D0 (enExample)
IL (1) IL256511B (enExample)
MX (1) MX2018001009A (enExample)
RU (1) RU2747733C1 (enExample)
SG (1) SG10201912416QA (enExample)
WO (1) WO2017021701A1 (enExample)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201505858VA (en) 2013-01-28 2015-09-29 St Jude Childrens Res Hospital A chimeric receptor with nkg2d specificity for use in cell therapy against cancer and infectious disease
EP3143134B1 (en) 2014-05-15 2020-10-28 National University of Singapore Modified natural killer cells and uses thereof
GB201513540D0 (en) 2015-07-31 2015-09-16 King S College London Therapeutic agents
GB201514874D0 (en) 2015-08-20 2015-10-07 Autolus Ltd Cell
MA46995A (fr) 2016-12-03 2019-10-09 Acerta Pharma Bv Méthodes et compositions pour l'utilisation de lymphocytes t thérapeutiques en association avec des inhibiteurs de kinase
EP3336107A1 (en) * 2016-12-15 2018-06-20 Miltenyi Biotec GmbH Immune cells expressing an antigen binding receptor and a chimeric costimulatory receptor
EA201991204A1 (ru) 2016-12-22 2019-12-30 Университа Дельи Студи Манья Греча Катандзаро Моноклональное антитело против уникального сиалогликозилированного опухолеассоциированного эпитопа cd43
SG11201908492PA (en) 2017-03-27 2019-10-30 Nat Univ Singapore Truncated nkg2d chimeric receptors and uses thereof in natural killer cell immunotherapy
EP3601537A4 (en) 2017-03-27 2021-01-13 National University of Singapore STIMULATING CELL LINES FOR EX VIVO EXPANSION AND ACTIVATION OF NATURAL KILLER CELLS
KR20200054160A (ko) 2017-06-02 2020-05-19 주노 쎄러퓨티크스 인코퍼레이티드 입양 세포 요법을 사용한 치료를 위한 물품 제조 및 방법
EP3658578A1 (en) * 2017-07-26 2020-06-03 Cellectis Methods of antigen-dependent chimeric antigen receptor (car) immune cell selection
CN109971724B (zh) * 2017-12-28 2023-10-31 上海细胞治疗研究院 靶向ErbB受体家族且自表达PD-1抗体的CAR-T细胞及其用途
CN111801348A (zh) 2018-02-09 2020-10-20 新加坡国立大学 活化性嵌合受体及其在自然杀伤细胞免疫疗法中的用途
KR20200138741A (ko) 2018-04-02 2020-12-10 내셔널 유니버시티 오브 싱가포르 면역 세포에서 발현되는 막-결합 항-사이토카인 비-신호전달 결합제를 이용한 인간 사이토카인의 중화
CN110615842B (zh) * 2018-06-20 2023-05-09 上海隆耀生物科技有限公司 一种包含共刺激受体的嵌合抗原受体及应用
EP3587454A1 (en) * 2018-06-27 2020-01-01 Albert-Ludwigs-Universität Freiburg Chimeric antigen receptors that bind to prostate specific membrane antigen
JP7560882B2 (ja) 2018-08-29 2024-10-03 ナショナル ユニヴァーシティー オブ シンガポール 遺伝子修飾免疫細胞の生存及び増加を特異的に刺激するための方法
GB201900858D0 (en) * 2019-01-22 2019-03-13 Price Nicola Kaye Receptors providing targeted costimulation for adoptive cell therapy
GB201902277D0 (en) 2019-02-19 2019-04-03 King S College London Therapeutic agents
EP3773918A4 (en) 2019-03-05 2022-01-05 Nkarta, Inc. ANTI-CD19 CHEMERIC ANTIGEN RECEPTORS AND THEIR USE IN IMMUNOTHERAPY
CN113811327A (zh) * 2019-03-11 2021-12-17 卢西德生物有限公司 MUC1平行CAR(pCAR)治疗剂
SG11202111130SA (en) 2019-04-30 2021-11-29 Senti Biosciences Inc Chimeric receptors and methods of use thereof
US20230000913A1 (en) * 2019-08-13 2023-01-05 King's College London Immunoresponsive cells armoured with spatiotemporally restricted activity of cytokines of the il-1 superfamily
JP7723420B2 (ja) * 2019-08-28 2025-08-14 キングス・カレッジ・ロンドン Ｂ細胞標的化並列ＣＡＲ（ｐＣＡＲ）治療的薬剤
GB202003277D0 (en) 2020-03-06 2020-04-22 King S College London Therapeutic agents
JP2023522038A (ja) * 2020-04-17 2023-05-26 ２セブンティ バイオ インコーポレイテッド 修飾ｃｃｒポリペプチド及びその使用
AU2021312871A1 (en) * 2020-07-21 2023-02-09 Allogene Therapeutics, Inc. Chimeric antigen receptors with enhanced signaling and activities and uses thereof
WO2022036495A1 (en) 2020-08-17 2022-02-24 Utc Therapeutics Inc. Lymphocytes-antigen presenting cells co-stimulators and uses thereof
WO2022083668A1 (en) * 2020-10-21 2022-04-28 Nanjing Legend Biotech Co., Ltd. Use of a chimeric co-stimulatory receptor for cell therapy
AU2022327766A1 (en) * 2021-08-13 2023-12-14 Ludwig-Maximilians-Universität München Anti-csf1r car expressing lymphocytes for targeted tumor therapy
US20240350545A1 (en) * 2021-08-18 2024-10-24 Legend Biotech Ireland Limited Modified immune cells expressing tlr receptors
JP7732839B2 (ja) * 2021-10-14 2025-09-02 株式会社三共 遊技機
JP7732840B2 (ja) * 2021-10-14 2025-09-02 株式会社三共 遊技機
JP7732843B2 (ja) * 2021-10-14 2025-09-02 株式会社三共 遊技機
JP7732841B2 (ja) * 2021-10-14 2025-09-02 株式会社三共 遊技機
JP7732842B2 (ja) * 2021-10-14 2025-09-02 株式会社三共 遊技機
CA3237754A1 (en) 2021-11-15 2023-05-19 Neogene Therapeutics B.V. Engineered t cells with reduced tgf-beta receptor signaling
US20250108113A1 (en) 2021-12-30 2025-04-03 Tr1X, Inc. Cd4+ t cells expressing il-10 and chimeric antigen receptors and uses thereof
CN118510814A (zh) * 2022-05-10 2024-08-16 星尘生物科技(上海)有限公司 一种嵌合抗原受体及其应用
WO2024209084A1 (en) 2023-04-05 2024-10-10 Kings College London Parallel chimeric antigen receptors (pcars) and adaptor chimeric antigen receptors comprising alternative signalling domains and methods of use thereof
GB202403718D0 (en) 2024-03-14 2024-05-01 King S College London Therapeutic agents

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009509562A (ja) 2005-10-03 2009-03-12 キャンサー・リサーチ・テクノロジー・リミテッド αｖβ６ペプチドリガンド及びその活用
WO2014055668A1 (en) 2012-10-02 2014-04-10 Memorial Sloan-Kettering Cancer Center Compositions and methods for immunotherapy

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996025953A1 (en) * 1995-02-24 1996-08-29 The General Hospital Corporation Redirection of cellular immunity by receptor chimeras
US7446190B2 (en) 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
PT2856876T (pt) 2007-03-30 2018-03-28 Memorial Sloan Kettering Cancer Center Expressão constitutiva de ligantes co-estimulatórios em linfócitos t adotivamente transferidos
US9206440B2 (en) 2009-01-23 2015-12-08 Roger Williams Hospital Viral vectors encoding multiple highly homologus non-viral polypeptides and the use of same
EP2483301A1 (en) 2009-10-01 2012-08-08 The United States Of America, As Represented By The Secretary, Department of Health and Human Services Anti-vascular endothelial growth factor receptor-2 chimeric antigen receptors and use of same for the treatment of cancer
KR101976882B1 (ko) 2011-03-23 2019-05-09 프레드 헛친슨 켄서 리서치 센터 세포 면역요법용 방법 및 조성물
PE20141520A1 (es) 2011-07-29 2014-11-17 Univ Pennsylvania Receptores coestimuladores de cambio
US9833476B2 (en) 2011-08-31 2017-12-05 The Trustees Of Dartmouth College NKP30 receptor targeted therapeutics
MX2014010185A (es) 2012-02-22 2014-11-14 Univ Pennsylvania Uso de dominio de señalizacion cd2 en receptores de antigeno quimericos de segunda generacion.
EP2817330B1 (en) 2012-02-22 2020-07-08 The Trustees of the University of Pennsylvania Use of icos-based cars to enhance antitumor activity and car persistence
CN103483452B (zh) 2012-06-12 2021-08-13 上海细胞治疗集团有限公司 双信号独立的嵌合抗原受体及其用途
AU2013312838B2 (en) 2012-09-04 2018-11-29 Cellectis Multi-chain chimeric antigen receptor and uses thereof
US9365641B2 (en) 2012-10-01 2016-06-14 The Trustees Of The University Of Pennsylvania Compositions and methods for targeting stromal cells for the treatment of cancer
WO2014055657A1 (en) 2012-10-05 2014-04-10 The Trustees Of The University Of Pennsylvania Use of a trans-signaling approach in chimeric antigen receptors
WO2014124143A1 (en) 2013-02-06 2014-08-14 Anthrogenesis Corporation Modified t lymphocytes having improved specificity
LT2956175T (lt) 2013-02-15 2017-12-11 The Regents Of The University Of California Chimerinis antigeno receptorius ir jo panaudojimo būdai
US20160017286A1 (en) 2013-03-06 2016-01-21 The Trustees Of The University Of Pennsylvania Ikaros inhibition to augment adoptive t cell transfer
US20160015750A1 (en) 2013-03-09 2016-01-21 Baylor College Of Medicine Vascular-targeted t-cell therapy
KR20150131218A (ko) 2013-03-14 2015-11-24 벨리쿰 파마슈티컬스, 인크. T 세포 증식의 제어 방법
WO2014172584A1 (en) 2013-04-17 2014-10-23 Baylor College Of Medicine IMMUNOSUPPRESSIVE TGF-β SIGNAL CONVERTER
AU2014342020C1 (en) 2013-10-31 2019-09-05 Fred Hutchinson Cancer Research Center Modified hematopoietic stem/progenitor and non-T effector cells, and uses thereof
WO2015075468A1 (en) 2013-11-21 2015-05-28 Ucl Business Plc Cell
EP3087101B1 (en) 2013-12-20 2024-06-05 Novartis AG Regulatable chimeric antigen receptor
CN106164599B (zh) * 2013-12-26 2019-07-05 巍然科技私人有限公司 加热或冷却流体流的流体处理装置和方法
US20170233452A1 (en) 2014-04-23 2017-08-17 Immusoft Corporation Chimeric antigen receptors specific to avb6 integrin and methods of use thereof to treat cancer
MX2017000646A (es) 2014-07-15 2017-04-27 Juno Therapeutics Inc Celulas geneticamente modificadas para terapia celular adoptiva.
WO2016014565A2 (en) 2014-07-21 2016-01-28 Novartis Ag Treatment of cancer using humanized anti-bcma chimeric antigen receptor
AU2015380397B2 (en) 2015-01-31 2021-10-21 The Trustees Of The University Of Pennsylvania Compositions and methods for T cell delivery of therapeutic molecules
WO2016196388A1 (en) 2015-05-29 2016-12-08 Juno Therapeutics, Inc. Composition and methods for regulating inhibitory interactions in genetically engineered cells
GB201513540D0 (en) * 2015-07-31 2015-09-16 King S College London Therapeutic agents
CN113811327A (zh) * 2019-03-11 2021-12-17 卢西德生物有限公司 MUC1平行CAR(pCAR)治疗剂

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009509562A (ja) 2005-10-03 2009-03-12 キャンサー・リサーチ・テクノロジー・リミテッド αｖβ６ペプチドリガンド及びその活用
WO2014055668A1 (en) 2012-10-02 2014-04-10 Memorial Sloan-Kettering Cancer Center Compositions and methods for immunotherapy
JP2015535689A (ja) 2012-10-02 2015-12-17 メモリアル スローン−ケタリング キャンサー センター 免疫療法のための組成物および方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
J.Immunol.(2013)Vol.191, p.4589-4598
Mol Med.(2012)Vol.18, p.565-576

Also Published As

Publication number Publication date
RU2747733C1 (ru) 2021-05-13
JP2021168675A (ja) 2021-10-28
US10865231B2 (en) 2020-12-15
CN107735407B (zh) 2022-08-16
WO2017021701A1 (en) 2017-02-09
MX2018001009A (es) 2018-06-07
DK3328880T3 (da) 2021-08-30
CA2993746A1 (en) 2017-02-09
US20190002521A1 (en) 2019-01-03
US20200331981A1 (en) 2020-10-22
IL256511B (en) 2021-09-30
EP3328880B1 (en) 2021-07-07
US10899818B2 (en) 2021-01-26
AU2016303355B2 (en) 2020-08-06
JP2018521663A (ja) 2018-08-09
SG10201912416QA (en) 2020-02-27
CN107735407A (zh) 2018-02-23
EP3939992A1 (en) 2022-01-19
US11802143B2 (en) 2023-10-31
KR102411571B1 (ko) 2022-06-21
ES2883633T3 (es) 2021-12-09
EP3328880A1 (en) 2018-06-06
IL256511A (en) 2018-02-28
GB201513540D0 (en) 2015-09-16
US20240228576A1 (en) 2024-07-11
US20200277353A1 (en) 2020-09-03
US20240076348A1 (en) 2024-03-07
US20210095000A1 (en) 2021-04-01
AU2016303355A1 (en) 2018-01-04
HK1256383A1 (en) 2019-09-20
US10703794B2 (en) 2020-07-07
KR20180028528A (ko) 2018-03-16

Similar Documents

Publication Publication Date Title
JP7053037B2 (ja) 治療薬
JP2022522654A (ja) Ｐｄ－１外部ドメインを担持するキメラサイトカイン受容体
CN111247242A (zh) 嵌合抗原受体(CARs)、组合物及其使用方法
CA2735456A1 (en) Method and compositions for enhanced anti-tumor effector functioning of t cells
CN113811327A (zh) MUC1平行CAR(pCAR)治疗剂
JP2020537521A (ja) 細胞
US20230277670A1 (en) Chimeric molecules providing targeted costimulation for adoptive cell therapy
JP7723420B2 (ja) Ｂ細胞標的化並列ＣＡＲ（ｐＣＡＲ）治療的薬剤
CN111479918A (zh) 细胞
JP2025511872A (ja) 多部位受容体及びシグナル伝達複合体
US20230331808A1 (en) Chimeric molecules providing targeted costimulation for adoptive cell therapy
HK1256383B (en) Therapeutic agents
JP2022001021A (ja) Ｃｄ２６特異的キメラ抗原受容体
TW202216752A (zh) 用於過繼細胞療法之提供靶向共刺激之嵌合分子

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190712

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190712

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20200417

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200602

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200902

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20200903

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20210309

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210709

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20210709

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20210709

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20210906

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20210907

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211207

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220302

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220315

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220324

R150 Certificate of patent or registration of utility model

Ref document number: 7053037

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250